Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

Healthy Clinical Trial

Official title: A Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

Status Completed

Clinical Trial Summary

The purpose of study is to evaluate safety, tolerability and pharmacokinetics of EB-203 Drops in adult healthy volunteers.

condition/disease : AMD(Age-related Macular Degeneration) Intervention/treatment : EB-203 or Placebo Phase : Phase I

Clinical Trial Description

Study Title : A Phase I clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

Purpose : The purpose of study is to evaluate safety, tolerability and pharmacokinetics of EB-203 Drops in adult healthy volunteers

Number of Site : One site (INJE UNIVERSITY BUSAN PAIK HOSPITAL)

A total of 8 subjects will be dosed in each group(Group B, C, D) with subjects randomized 3:1 to EB-203 or placebo.(A total of 4 subjucts will be dosed in Group A) Up to 28 subjects will be enrolled in four consecutive cohorts. A safety data review as masking will be performed for 4days prior repeated treatment. Treatment of high dose will proceed following a review of safety data from low dose.

Safety and tolerability assessments and drug plasma concentrations will be evaluated throughout the study in all cohorts.

Outcome Measures :

1. Primary Outcome Measures

: Frequency of AEs (Adverse Events) and ADR (Adverse Drug Reaction)

2. Secondary Outcome Measures : Pharmacokinetic variables evaluation for single and repeated dose administration.

Safety Assessment :

• V/S, Physical Exam, Laboratory Exam, ECG

• Ophthalmic Exam

Investigational product(IP) :

• Active Comparator : 1 %, 2 %, 4 %, 8% of EB-203

• Placebo Comparator : Placebo

Intervention&Number of Subject : Total 28 subjects (A Group 4, B~D Group 8)

Inclusion Criteria :

1. Healthy adult males between the ages of 20 and 55 years

2. Body Weight > 55 kg and BMI 18 ~ 27 kg/m2

3. Patients signed informed consent willing and able to sign informed consent form and comply with visit and study procedures per protocol

Exclusion Criteria :

1. A person who has a history or presence of clinical significant Cardiovascular, Respiratory, Hepatobiliary, Renal/Urinary, Hematological, Gastrointestinal, Endocrine, Neurological, Psychiatric disease

2. A person who has the following diseases from medical and ophthalmic examination

• Suspected symptoms or signs of visual organ disease including corneitis, uveitis, retinitis, dry eyes, and strabismus

• Corrected visual acuity < 20/25 or Intraocular Pressure > 21 mmHg

• Patients who have received any eye surgery

• Other abnormal findings in ophthalmic examinations

3. Other patients considered by investigators to be inappropriate as subjects. ;

Related Conditions & MeSH terms

• Healthy

• NCT number: NCT05538949
• Study type: Interventional
• Source: EyebioKorea, Inc.
• Status: Completed
• Phase: Phase 1
• Start date: June 29, 2022
• Completion date: October 7, 2022